UBS Reiterates Hold Rating for Ionis Pharmaceuticals with $46 Price Target

UBS has maintained a Hold rating for Ionis Pharmaceuticals with a price target of $46.00. The company's shares opened at $40.87. Additionally, Ionis Pharmaceuticals received a Hold from TR | OpenAI – 4o's Dex Genotek and a Buy rating from Leerink Partners. The company has a one-year high of $50.43 and a one-year low of $23.95, with an average volume of 1.8M.

UBS has maintained a Hold rating for Ionis Pharmaceuticals (IONS), with a price target of $46.00, as reported by Esther Rajavelu. The company's shares opened at $40.87 on July 2, 2025. This rating reflects recent performance and strategic developments at Ionis, which has been focused on advancing its portfolio of RNA-targeting therapeutics.

Key metrics from the second quarter of 2025 highlight the company's operational efficiency and financial health. Revenue (GAAP) for Q2 2025 was $2.92 million, falling short of the $9.43 million analyst estimate. Research and development expenses (GAAP) jumped 77.3% year over year, primarily due to increased clinical program expenses for zelenectide pevedotin development. Despite the increase in R&D expenses, the cash balance remains substantial at $721.5 million as of Q2 2025 (GAAP), though net loss (GAAP) increased to $(1.14) per share from $(0.77) per share in Q2 2024 [1].

Looking ahead, investors may wish to monitor updates on the Duravelo-2 trial for zelenectide pevedotin, with dose selection and possible U.S. FDA pathway clarification expected in Q4 2025. Progress with its BRC radioconjugates and milestones from its ongoing partnerships are also anticipated as events that could generate value or update investors in the next reporting periods [1].

Ionis Pharmaceuticals received a Hold rating from TR | OpenAI – 4o's Dex Genotek and a Buy rating from Leerink Partners. The company has a one-year high of $50.43 and a one-year low of $23.95, with an average volume of 1.8 million shares.

References:
[1] https://www.ainvest.com/news/ionis-pharmaceuticals-neutral-rating-ubs-46-price-target-2508/
[2] https://www.tradingview.com/news/tradingview:7a43027da8bc8:0-ionis-pharmaceuticals-officer-sells-shares/